Fox Run Management’s Edgewise Therapeutics EWTX Stock Holding History

Fox Run Management’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$244K	Sell	6,014 -1,962	-25%	-$67.6K	0.04%	751
2026 Q1	$242K	Sell	7,976 -4,384	-35%	-$126K	0.04%	699
2025 Q4	$307K	Sell	12,360 -8,111	-40%	-$163K	0.05%	691
2025 Q3	$332K	Buy	+20,471	New	+$290K	0.05%	649
2024 Q2	–	Sell	-10,814	Closed	-$197K	–	861
2024 Q1	$197K	Buy	+10,814	New	+$172K	0.04%	640
2023 Q1	–	Sell	-18,105	Closed	-$162K	–	743
2022 Q4	$162K	Buy	+18,105	New	+$170K	0.07%	516

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fox Run Management's EWTX Position: Q2 2026 in Review

Fox Run Management reduced its Edgewise Therapeutics (EWTX) stake by 25% in Q2 2026, selling an estimated $67.6K and leaving 6,014 shares worth $244K. The position accounts for 0.04% of the portfolio, ranked #751.

Fox Run Management first reported a position in EWTX in Q4 2022 and has held it in 6 quarters since. The position peaked at $332K in Q3 2025. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

Fox Run Management held 6,014 shares of Edgewise Therapeutics worth $244K as of Q2 2026.
Fox Run Management sold 1,962 Edgewise Therapeutics shares in Q2 2026, an estimated $67.6K.
Edgewise Therapeutics made up 0.04% of Fox Run Management's portfolio in Q2 2026, its #751 holding.
Fox Run Management first reported a position in Edgewise Therapeutics in Q4 2022 and has held it in 6 quarters since.
Fox Run Management's Edgewise Therapeutics position peaked at $332K in Q3 2025.
223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.